Static, one-size-fits-all clinical supply chains create waste, delay trial milestones and heighten compliance risk, pressures now intensified by the EU Clinical Trials Regulation. In response, biotechs are shifting from large safety stocks to flexible, data-driven, patient-centric models that pair real-time enrollment forecasting with agile labeling and regional depots. “The most critical KPI in a clinical…